

Base Demand Forecast

“v15”, prepared in 2017



December, 2017

Reach every child

www.gavi.org

Introduction

This is the second publication of the Base Demand Forecast that describes the volume projections that inform Gavi's financial forecast and impact projections. This publication was prepared in 2017 and aligns with the "v15" financial forecast cycle.

The publication is intended to improve the transparency and timeliness of demand forecasts shared with Gavi partners, industry and the public. The Base Demand Forecast is published annually following Gavi's 4th quarter Board meeting where the financial forecast is reviewed. In general, the forecast will be published in December or January each year.

This publication includes tables describing volumes associated with two different country scopes. The first table summarizes volumes for forecasts that generally considered the 73 countries that were eligible for Gavi support as of 2011. This set of countries is labelled "Gavi 73". The second table summarizes actual and forecasted volumes that considered 65 countries, defined as the same "Gavi 73" countries but excluding India, Indonesia, Ukraine and five Pan American Health Organization (PAHO) countries. The "Gavi 65" country scope is designed to help improve the consistency across actuals and forecasted periods given that actual shipments reported by UNICEF are often limited in scope to the 65 countries.

The volumes presented include doses regardless of actual or projected funding source. The figures include doses projected to be funded by Gavi and doses co-financed by supported countries. In addition, the volumes include doses projected to be fully self-financed by countries that have transitioned from Gavi support, as well as estimated demand for programmes that introduce without Gavi support. Volumes reflect supply constraints where relevant.

There are a number of important nuances in the volume forecasts that have been footnoted to the extent possible. In general, the base demand forecast publication seeks to find a balance on describing some of the key complexities while still keeping this publication relatively simple for its intended purpose. Nevertheless, we recognize there may be additional details and explanation that will be required for some audiences and purposes. Users of this new publication can contact forecast@gavi.org if they require further guidance or information.

Feedback and suggestions for improvement on this new demand forecast publication are also welcomed. Please send comments to forecast@gavi.org.

Total Gavi 73 Volume by Vaccine, doses, millions

Table A. Total Volumes for "Gavi 73" by Vaccine, doses, millions

Vaccine	Forecasted															Total
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	
Pentavalent (DTP-Hib-HepB)							267	243	255	258	260	262	264	266	268	2,343
Pneumococcal conjugate vaccine (PCV)							162	158	162	171	184	196	210	221	235	1,698
Rotavirus							85	106	124	133	149	171	186	198	208	1,359
Measles-Rubella (MR)							348	440	206	170	341	515	284	293	338	2,935
Measles							148	130	115	76	41	6	13	2	14	545
Human papillomavirus (HPV)							3	8	29	45	41	44	48	39	47	303
Inactivated Polio Vaccine (IPV)							44	65	66	71	57	58	58	59	60	539
Meningitis A (MenA)							35	76	36	44	38	39	40	41	42	391
Yellow Fever (YF)							22	59	78	71	78	86	80	77	56	607
Japanese encephalitis (JE)							46	34	34	49	41	47	50	51	50	402
Total of above							1,161	1,319	1,105	1,088	1,230	1,423	1,233	1,247	1,317	11,122

Sources

Forecasted doses are from the demand forecast used to inform the v15 Gavi financial forecast reviewed by the Gavi Board at its November 2017 meeting

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus.
- Men A and YF rows do not account for volumes associated with stockpiles.
- Gavi support for IPV is based on earmarked funding for the 2014-2019 period. This version of the forecast assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations.
- TCV is not included in this table as the v15 forecast focussed on the Gavi 65; a Gavi 73 view of TCV will be included in the next version

Total Gavi 65 Volume by Vaccine, doses, millions

Table B. Total Volumes for "Gavi 65" by Vaccine, doses, millions

Vaccine	<i>Actuals</i>					<i>Forecasted</i>										Total
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	
Pentavalent (DTP-Hib-HepB)	133	154	148	136	144	151	168	142	155	158	160	162	165	167	169	2,311
Pneumococcal conjugate vaccine (PCV)	27	47	61	106	120	139	151	129	137	141	145	147	148	152	158	1,808
Rotavirus	1	8	18	37	36	45	58	65	77	84	90	99	102	105	107	932
Measles-Rubella (MR)	0	0	88	86	32	23	90	145	102	86	256	430	198	208	252	1,995
Measles	0	10	115	22	52	28	87	105	115	76	41	6	13	2	14	686
Human papillomavirus (HPV)			1	1	2	2	2	7	28	38	33	35	38	28	35	250
Inactivated Polio Vaccine (IPV)				4	31	46	38	59	59	65	50	51	52	53	53	560
Meningitis A (MenA)	0	56	53	68	68	30	35	76	36	44	38	39	40	41	42	666
Yellow Fever (YF)	14	16	20	31	31	36	22	58	78	71	75	86	80	77	56	750
Japanese encephalitis (JE)				0	2	9	19	4	4	18	9	6	15	15	13	112
Typhoid Conjugate Vaccine (TCV)									10	22	36	56	81	91	104	399
Total of above	174	292	503	490	518	508	669	791	801	803	933	1,116	932	938	1,003	10,471

Sources

Actual volumes are based on shipment reports published by UNICEF Supply Division. Forecasted volumes are from the demand forecast aligned with the v15 Gavi financial forecast reviewed by the Gavi Board at its November 2017 meeting

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The scope of countries considered in actuals and forecasted values is generally 65 countries: the "Gavi 73" less India, Indonesia, Ukraine, and five PAHO countries.
- The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus.
- Men A and YF rows do not account for volumes associated with stockpiles
- Actual volumes should be interpreted as minimums in some vaccines where there is significant procurement through channels other than UNICEF
- Gavi support for IPV is based on earmarked funding for the 2014-2019 period. This version of the forecast assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations.

Thank you



Reach every child

www.gavi.org